Complement Regulation to Undo Systemic Harm in Preeclampsia

Phase 2 Terminated 2 enrolled Cedars-Sinai Medical Center Alexion Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.

Timeline

Start: 2021-09-13
Primary completion: 2021-12-07
Completion: 2021-12-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eculizumab	Monoclonal antibody	1200 mg	Intravenous

Complement Regulation to Undo Systemic Harm in Preeclampsia

Summary

Timeline

Drugs

Indications